

Action Plan for the Prevention, Care & Treatment of Viral Hepatitis

Updated 2014-2016

Background, Highlights & Priorities


Corinna Dan, RN, MPH

Office of HIV/AIDS and Infectious Disease Policy Department of Health and Human Services



Viral Hepatitis Action Plan Priorities

- 1. Educating providers and communities to reduce health disparities
- 2. Improving testing, care, and treatment to prevent liver disease and cancer
- 3. Strengthening surveillance to detect viral hepatitis transmission and disease
- 4. Eliminating transmission of vaccinepreventable viral hepatitis
- 5. Reducing viral hepatitis cases caused by drug-use behaviors
- 6. Protecting patients and workers from health-care-associated viral hepatitis





Implementation Group Members and Affiliations









































Members without logos:

Office of HIV/AIDS and Infectious Disease Policy Regional Health Administrators




Proposed 2020 Goals of the Viral Hepatitis Action Plan (full implementation)

- Increase the proportion of persons who are aware of their HBV infection from 33% to 66%
- Increase the proportion of persons who are aware of their HCV infection from 45% to 66%
- Reduce the number of new HCV infections by 25%
- Eliminate mother-to-child HBV transmission





Gaps in the U.S. HCV Continuum of Care



Chronic HCV-Infected; N=3,500,000.

Yehia et al, PLOS One, 2014

[†] Calculated as estimated number chronic HCV-infected (3,500,000) x estimated percentage diagnosed and aware of their infection (49.8%); n=1,743,000. ± Calculated as estimated number diagnosed and aware (1,743,000) x estimated percentage with access to outpatient care (86.9%); n=1,514,667.

[§] Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage HCV RNA confirmed (62.9%); n=952,726.

^{||} Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage who underwent liver biopsy (38.4%); n=581,632.

[¶] Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage prescribed HCV treatment (36,7%); n=555,883.


^{**} Calculated as estimated number prescribed HCV treatment (555,883) x estimated percentage who achieved SVR (58.8%); n=326,859. Note: Only non-VA studies are included in the above HCV treatment cascade.



CDC & USPSTF Recommendations for HCV Testing

- One time screening test for persons born 1945-1965
- Major risk
 - Past or present injection drug use
- Other risks
 - Received blood/organs prior to June 1992
 - Received blood products made prior to 1987
 - > Ever on chronic hemodialysis
 - Infants born to HCV infected mothers
 - > Intranasal drug use
 - Unregulated tattoo
 - History of incarceration
- Medical
 - Persistently elevated ALT (liver enzymes)
 - > HIV infection (annual testing)






MMWR Aug 2012. Moyer VA, Ann Int Med 2013.




Reported Number of Acute Hepatitis C Cases — U.S., 2000–2012



nal Notifiable Disea



2013 HCV Consultation Findings




- Drug use is an increasing problem in rural and semirural America
- Multi-component prevention strategies are needed
- Viral hepatitis testing and surveillance must improve to guide prevention

Full report available at www.aids.gov/hepatitis and Valdiserri RO, Khalsa J, Dan C, et al. Confronting the Emerging Epidemic of HCV Infection Among Young Injection Drug Users. *Am J Public Health*. 2014 Mar 13.



Affordable Care Act Opportunities

- Elimination of preexisting condition restrictions
- Expanded access to health insurance
- Preventive health care coverage
 - Screening
 - USPSTF Grade A or B
 - Vaccination
 - ACIP recommended





Viral Hepatitis Action Plan & The Role of Stakeholders

The updated VHAP underscores that its national goals cannot be achieved through federal action alone.

Active involvement, and innovation, from a broad mix of nonfederal stakeholders from various sectors, both public and private, is essential.

The VHAP provides a framework and focus around which all stakeholders can engage to strengthen the nation's response to viral hepatitis.



Stakeholders' Workbook

reak the Silence • Prevent • Test • Treat • Cure • Break th vent • Test • Treat • Cure • Break the Silence • Prevent • Cure • Break the Silence • Prevent • Test • Treat • Cure • te • Prevent • Test • Treat • Cure • Break the Silence • Predent • Test • Treat • Cure • Break the Silence • Prevent • Test •



STAKEHOLDERS' WORKBOOK Exploring Vital Roles and Opportunities to Break the Silence

Action Plan for the Prevention, Care,
& Treatment of Viral Hepatitis

Updated 2014-2016

Developed by the Office of HIV/AIDS and Infectious Disease Policy for planning purposes only





Purpose:

Facilitate opportunities to talk through potential activities, challenges, tools, resources, and partnerships related to each priority area.

- Discussion questions provided, e.g.:
 - What are the best ways to identify persons with chronic viral hepatitis who do not know they are infected? What can your organization do to promote this?
- Sample hepatitis planning sheet to prioritize, set timeframes, & measures

CALL TO ACTION



Be the Action in the Viral Hepatitis Action Plan!

- The Action Plan provides a framework and a focus to address viral hepatitis in the U.S.
- Individuals, HIV Prevention and Care programs, health care providers, health systems, and industry partners all play crucial roles and are part of the VHAP.
- Reports, blogs, updates @ www.AIDS.gov/hepatitis